People · Operator
Named in public records as an officer, director or promoter · active 2013–2015 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ImmuneXcite, Inc. | — | Biotechnology | Series A | $17.6M | $96.6M | 2013 |
| Novalere FP, Inc. | — | Pharmaceuticals | Series A | $6.5M | $201.3M | 2013 |
Valerie Friedman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Valerie Friedman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Cohen | 1 | 38 |
| Ann DeWitt | 1 | 10 |
| John Edwards | 1 | 8 |
| Chen Schor | 1 | 4 |
| Eric Rowinsky | 1 | 4 |
| Eric Furfine | 1 | 3 |
| James Geraghty | 1 | 3 |
| Stonberg Jeff | 1 | 1 |
| David Schechter | 1 | 1 |
| Yaniv Bejerano | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.